Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction.
Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction.
复制标题
醋丁洛尔可减少急性心肌梗死患者的早期室性心律失常。
DOI：
10.1136/hrt.41.6.654
复制
发表时间：
1979
影响因子：
--
通讯作者：
R. Roberts
中科院分区：
文献类型：
--
作者：
G. Ahumada;R. Karlsberg;A. Jaffe;H. Ambos;And BURTON E. SOBEL;R. Roberts
为了评估静脉注射醋丁洛尔（每 4 小时 1-20 毫克，持续 24 小时）对心律和功能的影响，我们研究了 72 名患有进展性心肌梗死的患者。 25 名患者在血浆肌酸激酶水平首次升高后 6 小时开始接受醋丁洛尔治疗。将酶法估计的梗塞面积与 25 个与预测梗塞面积匹配的对照进行比较。观察到的梗塞大小在两组中没有显着差异（分别为 37 +/- 5 和 30 +/- 5 CK 克当量）。在醋丁洛尔治疗期间，平均心率、舒张压和心输出量较对照值有所下降，但仍保持在正常范围内。平均肺动脉压和肺动脉闭塞压没有变化。在一组 22 名接受治疗的患者与 22 名对照受试者的室性期前收缩频率方面相匹配，醋丁洛尔可迅速降低室性期前收缩和重复性心律失常的频率，而在相应的时间间隔内，对照组的值没有显着变化。因此，对于某些急性心肌梗塞患者来说，醋丁洛尔可能是一种有用的抗心律失常药物，这些患者会不利地改变血流动力学稳定性或酶法估计的梗塞面积。
To assess the effects of intravenously administered acebutolol (1-20 mg every 4 hours for 24 hours) on cardiac rhythm and performance, we studied 72 patients with evolving myocardial infarction. Twenty-five patients were treated with acebutolol beginning 6 hours after the first increase in the level of plasma creatine kinase. Enzymatically estimated infarct size was compared with that of 25 controls matched for predicted infarct size. Observed infarct sizes were not significantly different in the 2 groups (37 +/- 5 and 30 +/- 5 CK-gram equivalents, respectively). Mean heart rate, diastolic blood pressure, and cardiac output declined from control values during treatment with acebutolol, but remained within the normal range. Mean pulmonary artery pressure and pulmonary artery occlusive pressure were unchanged. In a group of 22 treated patients matched with 22 control subjects for frequency of ventricular extrasystoles, acebutolol effected a prompt reduction in frequencies of ventricular extrasystoles and repetitive arrhythmias, whereas values were not significantly changed in controls during the corresponding intervals. Accordingly, acebutolol may be a useful antiarrhythmic agent in selected patients with acute myocardial infarction with adversely altering haemodynamic stability or enzymatically estimated infarct size.